RCAG
LSTA icon

Rehmann Capital Advisory Group’s Lisata Therapeutics LSTA Stock Holding History

Rehmann Capital Advisory Group’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$28 Hold
1
– – ﹤0.01% 1686
2019
Q2 		$25 Hold
1
– – ﹤0.01% 2060
2019
Q1 		$39 Hold
1
– – ﹤0.01% 2077
2018
Q4 		$39 Hold
1
– – ﹤0.01% 1821
2018
Q3 		$64 Hold
1
– – ﹤0.01% 2116
2018
Q2 		$71 Buy
+1
New +$71 ﹤0.01% 2096

Other funds holding LSTA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
WB
WesBanco Bank Wheeling, West Virginia $3.61B AUM 24.09% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Rehmann Capital Advisory Group's LSTA Position: Q3 2019 in Review

Rehmann Capital Advisory Group held its Lisata Therapeutics (LSTA) position steady in Q3 2019 at 1 share worth $28. The position accounts for ﹤0.01% of the portfolio, ranked #1686.

Rehmann Capital Advisory Group first reported a position in LSTA in Q2 2018 and has held it in 6 quarters since. The position peaked at $71 in Q2 2018. 25 funds tracked by Wall St. Rank hold LSTA as of Q3 2019.

  • Rehmann Capital Advisory Group held 1 share of Lisata Therapeutics worth $28 as of Q3 2019.
  • Rehmann Capital Advisory Group left its Lisata Therapeutics share count unchanged in Q3 2019.
  • Lisata Therapeutics made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1686 holding.
  • Rehmann Capital Advisory Group first reported a position in Lisata Therapeutics in Q2 2018 and has held it in 6 quarters since.
  • Rehmann Capital Advisory Group's Lisata Therapeutics position peaked at $71 in Q2 2018.
  • 25 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.